Previous 10 | Next 10 |
Shares of Invitae (NYSE: NVTA) were crashing 15.4% lower as of 3:16 p.m. ET on Tuesday. The steep decline came after the medical genetics company announced several developments on Monday that rattled investors. Invitae revealed a shakeup in its executive ranks. CEO Sean George h...
Invitae ( NYSE: NVTA ) shares are down 16% in Tuesday afternoon as investors deal with the aftermath of a slew of post-market news from the medical genetics company after Monday's closing bell. Besides having the company's COO take over as CEO effective immediately...
Invitae ( NYSE: NVTA ) downgraded to Marketperform from Outperform at SVB Securities; also Benchmark downgraded it to Hold from Buy. It is expected that the company will undergo strategic restructuring as part of cost reduction plan. Year to date, shares are ...
Gainers: Sidus Space ( SIDU ) +34% . DermTech ( DMTK ) +25% . Eos Energy Enterprises ( EOSE ) +24% . NuCana ( NCNA ) +21% . Power REIT ( PW ) +21% . Apellis Pharmaceuticals ( APLS ) +20% . Silvergate ( SI ) ...
A potential M&A deal took a share of the spotlight in Tuesday's midday trading. NCR ( NYSE: NCR ) rallied on reports that it has entered exclusive talks with a private equity firm. Meanwhile, earnings news remains a key driver as well. Silvergate Capital ( SI ) represent...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: motorolka / Shutterstock.com Invitae (NYSE: NVTA ) stock is falling on Tuesday after the biotechnology company revealed plans to cut costs as part of a strategic realignment. According to a press rele...
Gainers: Apellis Pharmaceuticals APLS +22% . Neuronetics STIM +17% . Nyxoah ( NYXH ) +17% . Celyad Oncology ( CYAD ) +8% . NuCana ( NCNA ) +7% . Losers: High Tide HITI -21% . Ultragenyx Pharmaceutical ( RARE ...
High Tide ( HITI ) -19% after proposes to raise C$10M in equity offering . Invitae ( NVTA ) -9% after guides Q2 revenue below consensus ; announces strategic realignment. INTELLIGENT LIVING APPLICATION ( ILAG ) -6% . International Business M...
Company announces actions to lower near-term cash burn. Revenue growth targets come in well below expectations. Stock could easily re-test its 2022 low. Back in March, I detailed how genetics company Invitae ( NVTA ) could massively dilute investors in the coming mon...
Invitae ( NYSE: NVTA ) will undertake an operational realignment that the medical genetics company said will lead to $326 million in annual cost savings by 2023. Shares are down 1.5% in after-hours trading. The move will also extend's Invitae's ( NVTA ) cash ru...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...